Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RN7SL219P is a human pseudogene belonging to the 7SL RNA family, derived from the functional 7SL RNA gene, also known as RN7SL1, which is the RNA component of the signal recognition particle (SRP). The 7SL RNA family provides the scaffold for SRP, a ribonucleoprotein complex essential for co-translational targeting of proteins to the endoplasmic reticulum membrane[1][3]. Pseudogenes like RN7SL219P are non-coding sequences that have lost their protein-coding or functional RNA expression due to mutations. Such pseudogenes typically do not encode functional RNA or protein but may, in rare cases, exert regulatory effects on gene expression via RNA interference, miRNA competition, or serving as decoys for RNA-binding proteins[4][6]. There is no evidence for active transcription, biological function, therapeutic targeting, or clinical significance specific to RN7SL219P as of current knowledge[2][7]. 7SL RNA pseudogenes are numerous in the human genome, largely as a result of retrotransposition events, and most are truncated and nonfunctional[7]. Only a few "parental" 7SL RNA genes are functional; the remainder are considered genomic fossils[7]. RN7SL219P is not considered a canonical biological target because it is a nonfunctional pseudogene and not a protein, receptor, enzyme, or other molecule subject to pharmacological modulation. Listing it as a target is likely incorrect in a therapeutic or drug-discovery context[2][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, 7SL, cytoplasmic 219, pseudogene (RN7SL219P).